Skip to main content

Utility Menu

  • HFSA Virtual ASM
  • COVID-19
  • Meetings
  • News
  • Journal
  • Learning Center
  • Member Login
Home

Main navigation

  • About Us
    • Board of Directors
    • Committees
    • Event Endorsement Guidelines
    • Financials
    • HFSA Staff
    • Sponsorship
    • Strategic Plan
  • Membership
    • Join or Renew
    • Membership Benefits and Types
    • Membership Directory
    • Member Login
    • Corporate Membership
  • Professional Development
    • Awards
    • Continuing Education
      • HFSA Virtual Annual Scientific Meeting 2020
      • HFSA Virtual Board Certification Review 2020
    • Heart Failure Certification (HF-Cert)
    • Fellowship Designation Program (FHFSA)
    • ERAS/NRMP Match for AHFTC Fellowship
    • HFSA Career Center
    • HFSA Learning Center
    • Heart Failure Beat Podcast
    • Professional Development News
  • Research
    • Heart Failure Beat Podcast
    • Journal of Cardiac Failure
    • Published Papers & Guidelines
    • Surveys
    • HFSA Research Network
    • Industry News
  • Advocacy
  • Patient Hub
    • Additional Resources for Patients
    • Heart Failure Awareness 365
    • Heart Failure Beat: Healthy Living Podcast
    • Heart Failure Clinical Trials Search
    • Heart Failure Facts
    • Heart Failure Patient and Caregiver Day 2020
    • Patient News
    • Patient Tools
    • Patient Resources for Providers
    • HFSA Coronavirus (COVID-19) Resources
  • Coronavirus (COVID-19) Resources
  • HFSA Virtual ASM
  • COVID-19
  • Meetings
  • News
  • Journal
  • Learning Center
  • Member Login
Facebook
Youtube
Twitter
Linkedin

Breadcrumb

  1. Home
  2. Industry News

Industry News

US FDA accepts supplemental New Drug Application for Jardiance® (empagliflozin) for adults with heart failure with reduced ejection fraction

  • Read more about US FDA accepts supplemental New Drug Application for Jardiance® (empagliflozin) for adults with heart failure with reduced ejection fraction

New Jardiance® findings showed improved cardio-renal outcomes in adults with heart failure with reduced ejection fraction regardless of chronic kidney disease status

  • Read more about New Jardiance® findings showed improved cardio-renal outcomes in adults with heart failure with reduced ejection fraction regardless of chronic kidney disease status

Amgen, Cytokinetics And Servier Announce Topline Results From GALACTIC-HF, A Phase 3 Trial Of Omecamtiv Mecarbil In Patients With Heart Failure

  • Read more about Amgen, Cytokinetics And Servier Announce Topline Results From GALACTIC-HF, A Phase 3 Trial Of Omecamtiv Mecarbil In Patients With Heart Failure

Bristol Myers Squibb to Acquire MyoKardia for $13.1 Billion in Cash

  • Read more about Bristol Myers Squibb to Acquire MyoKardia for $13.1 Billion in Cash

Jardiance® reduced the combined relative risk of cardiovascular death and hospitalization for heart failure by 25% in adults with and without diabetes who had heart failure with reduced ejection fraction

  • Read more about Jardiance® reduced the combined relative risk of cardiovascular death and hospitalization for heart failure by 25% in adults with and without diabetes who had heart failure with reduced ejection fraction

Farxiga demonstrated unprecedented reduction in the risk of kidney failure and cardiovascular or renal death in patients with chronic kidney disease in the Phase III DAPA-CKD trial

  • Read more about Farxiga demonstrated unprecedented reduction in the risk of kidney failure and cardiovascular or renal death in patients with chronic kidney disease in the Phase III DAPA-CKD trial

Jardiance® meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in phase III trial in adults with and without diabetes

  • Read more about Jardiance® meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in phase III trial in adults with and without diabetes

Update on Merck's New Scientific Efforts to Help Combat COVID-19

  • Read more about Update on Merck's New Scientific Efforts to Help Combat COVID-19

Bayer Extends Clinical Development Program for Finerenone with Phase III Study in Patients with Heart Failure and Preserved Ejection Fraction

  • Read more about Bayer Extends Clinical Development Program for Finerenone with Phase III Study in Patients with Heart Failure and Preserved Ejection Fraction

MyoKardia Announces Primary and All Secondary Endpoints Met in Phase 3 EXPLORER Clinical Trial of Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy

  • Read more about MyoKardia Announces Primary and All Secondary Endpoints Met in Phase 3 EXPLORER Clinical Trial of Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy

Pagination

  • Page 1
  • Next page ››
Subscribe to Industry News

Leading experts on heart failure care

Our vision is to significantly reduce the burden of heart failure and provide a platform for collaboration, education, innovation, research, and advocacy to improve and expand care.

Learn more About HFSA

Get in touch

9211 Corporate Blvd., Suite 270 Rockville, MD 20850
(301) 312-8635
info@hfsa.org
Facebook
Youtube
Twitter
Linkedin

Footer menu

  • Contact
  • Media Center
  • Privacy Policy & Terms of Use